Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians attempt to achieve these goals by reducing excess fat mass, preventing weight regain, and addressing obesity-related comorbidities such as hypertension, dyslipidemia, and type 2 diabetes. Unlike other highly prevalent disorders in China, obesity lacks prescription drug treatments. However, this therapy market will experience strong growth over the forecast period, fueled by the launch and uptake of several GLP-1 receptor analogues, including semaglutide (Novo Nordisk’s Wegovy), tirzepatide (Eli Lilly’s Zepbound), Innovent Biologic’s mazdutide, and a fixed-dose combination of cagrilintide + semaglutide (Novo Nordisk’s CagriSema). In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will influence the launch and uptake of new therapies in this highly lucrative market.
Questions answered
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.